Search results for "Antibody"

showing 10 items of 1896 documents

AB052. P-20. Phase 2, open-label study of second-line M7824 treatment in patients with locally advanced or metastatic biliary tract cancer

2019

BACKGROUND: Transforming growth factor β (TGF-β) signaling promotes tumor immunosuppression; its inhibition in the tumor microenvironment may enhance the response to anti-PD-L1 treatment. M7824 is an innovative first-in-class bifunctional fusion protein composed of 2 extracellular domains of TGF-βRII (a TGF-β “trap”) fused to a human IgG1 mAb against PD-L1. Building upon encouraging efficacy observed in a phase 1 study, the present study will evaluate M7824 clinical benefit in patients with pretreated biliary tract cancer (BTC). METHODS: This multicenter, international trial is evaluating M7824 monotherapy in patients with locally advanced or metastatic (LA/M) BTC unselected for tumor PD-L1…

0301 basic medicineTumor microenvironmentBiliary tract cancerbiologybusiness.industrymedicine.drug_classMonoclonal antibodyFusion protein03 medical and health sciences030104 developmental biology0302 clinical medicine030220 oncology & carcinogenesisPD-L1Poster AbstractsCancer researchExtracellularbiology.proteinMedicineIn patientbusinessTransforming growth factor
researchProduct

Evaluation of Immunofluorescence Antibody Test Used for the Diagnosis of Canine Leishmaniasis in the Mediterranean Basin: A Systematic Review and Met…

2015

With an expected sensitivity (Se) of 96% and specificity (Sp) of 98%, the immunofluorescence antibody test (IFAT) is frequently used as a reference test to validate new diagnostic methods and estimate the canine leihmaniasis (CanL) true prevalence in the Mediterranean basin. To review the diagnostic accuracy of IFAT to diagnose CanL in this area with reference to its Se and Sp and elucidate the potential causes of their variations, a systematic review was conducted (31 studies for the 26-year period). Three IFAT validation methods stood out: the classical contingency table method, methods based on statistical models and those based on experimental studies. A variation in the IFAT Se and Sp …

0301 basic medicineVeterinary medicinelcsh:MedicineArtificial Gene Amplification and ExtensionPolymerase Chain ReactionMediterranean BasinMathematical and Statistical Techniques0302 clinical medicineZoonosesMedicine and Health SciencesCanine leishmaniasisDog Diseaseslcsh:ScienceLeishmaniasisMammalsMultidisciplinaryGeographymedicine.diagnostic_testMediterranean RegionGeographical regionsRegional geographyResearch AssessmentInfectious DiseasesFluorescent Antibody Technique DirectMeta-analysisVertebratesPhysical Sciencesmedicine.symptomStatistics (Mathematics)Research ArticleNeglected Tropical DiseasesSystematic Reviews030231 tropical medicine030106 microbiologyResearch and Analysis MethodsImmunofluorescenceSensitivity and SpecificityAsymptomatic03 medical and health sciencesDogsparasitic diseasesParasitic DiseasesmedicineAnimalsStatistical MethodsMolecular Biology TechniquesMolecular BiologyProtozoan Infectionsbusiness.industrylcsh:RfungiOrganismsReproducibility of ResultsBiology and Life SciencesLeishmaniasisGold standard (test)Tropical Diseasesmedicine.diseaseEarth sciencesParasitologyAmniotesImmunologyMediterranean BasinParasitologylcsh:QbusinessMathematicsMeta-AnalysisPLOS ONE
researchProduct

An overview on anti-tubulin agents for the treatment of lymphoma patients

2020

Anti-tubulin agents constitute a large class of compounds with broad activity both in solid tumors and hematologic malignancies, due to the interference with microtubule dynamics. Since microtubules play crucial roles in the regulation of the mitotic spindles, the interference with their function usually leads to a block in cell division with arrest at the metaphase/anaphase junction of mitosis, followed to apoptosis. This explains the reason why tubulin-binding agents (TBAs) proved to be extremely active in patients with cancer. Several anti-tubulin agents are indicated in the treatment of patients with lymphomas both alone and in combination chemotherapy regimens. The article reviews the …

0301 basic medicineVinca alkaloidsLymphomaMitosisAntineoplastic AgentsApoptosismacromolecular substancesMicrotubulesAntibody drug conjugatesTaxanes03 medical and health sciences0302 clinical medicineTubulinMicrotubulemedicineAnimalsHumansMaytansinePharmacology (medical)MetaphaseMitosisAnaphasePharmacologybiologybusiness.industryCancerCombination chemotherapymedicine.diseaseTubulin ModulatorsLymphoma030104 developmental biologyTubulinEpothilones030220 oncology & carcinogenesisbiology.proteinCancer researchDolastatinsbusinessPharmacology & Therapeutics
researchProduct

Silencing of Foxp3 enhances the antitumor efficacy of GM-CSF genetically modified tumor cell vaccine against B16 melanoma

2017

Antonio Miguel,1 Luis Sendra,1 Verónica Noé,2 Carles J Ciudad,2 Francisco Dasí,3,4 David Hervas,5 María José Herrero,1,6 Salvador F Aliño17 1Department of Pharmacology, Faculty of Medicine, University of Valencia, 2Department of Biochemistry and Molecular Biology, Faculty of Pharmacy, University of Barcelona, 3Research University Hospital of Valencia, INCLIVA Health Research Institute, 4Department of Physiology, Faculty of Medicine, University of Valencia Foundation, 5Biostatistics Unit, 6Pharmacogenetics Unit, Instituto de Investigación Sanitaria La Fe (IIS La Fe), 7Clinical Pharmacology Unit, ACM Hospital Univers…

0301 basic medicineantisense oligonucleotidemedicine.medical_treatmentCellImmunoteràpiaIpilimumabchemical and pharmacologic phenomenaImmunotheraphyVacuneslcsh:RC254-282OncoTargets and Therapy03 medical and health sciencesgene silencingCancer immunotherapymedicineGene silencingPharmacology (medical)IL-2 receptorCàncerOriginal ResearchTumorsCancerVaccinescancer immunotherapybiologybusiness.industryFOXP3hemic and immune systemslcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensVaccinationTreg030104 developmental biologymedicine.anatomical_structureantitumor vaccineOncologybiology.proteinCancer researchAntibodybusinessmedicine.drugOncoTargets and Therapy
researchProduct

AC‐1001 H3 CDR peptide induces apoptosis and signs of autophagy in vitro and exhibits antimetastatic activity in a syngeneic melanoma model

2016

Antibody-derived peptides modulate functions of the immune system and are a source of anti-infective and antitumor substances. Recent studies have shown that they comprise amino acid sequences of immunoglobulin complementarity-determining regions, but also fragments of constant regions. VH CDR3 of murine mAb AC-1001 displays antimetastatic activities using B16F10-Nex2 murine melanoma cells in a syngeneic model. The peptide was cytotoxic in vitro in murine and human melanoma cells inducing reactive oxygen species (ROS) and apoptosis by the intrinsic pathway. Signs of autophagy were also suggested by the increased expression of LC3/LC3II and Beclin 1 and by ultrastructural evidence. AC-1001 H…

0301 basic medicineautophagyimmunoglobulin CDRmedicine.drug_classBiologyMonoclonal antibodyGeneral Biochemistry Genetics and Molecular Biology03 medical and health sciencesImmune systemmedicinemelanomaCytotoxic T cellResearch ArticlesMelanomaAutophagyapoptosismedicine.diseaseMolecular biologyIn vitro030104 developmental biologyApoptosisCancer researchbiology.proteinpeptidesAntibodyResearch ArticleFEBS Open Bio
researchProduct

LBA-06 IMAB362: a novel immunotherapeutic antibody targeting the tight-junction protein component CLAUDIN18.2 in gastric cancer

2016

0301 basic medicinebiologyTight junctionbusiness.industryCancerHematologymedicine.disease03 medical and health sciences030104 developmental biology0302 clinical medicineOncology030220 oncology & carcinogenesisComponent (UML)Antibody targetingbiology.proteinCancer researchmedicineAntibodybusinessAnnals of Oncology
researchProduct

Translation of Basic Research into Clinics: Killer Immunoglobulin-like Receptors Genes in Autoimmune and Infectious Diseases

2018

Killer immunoglobulin-like receptors (KIRs) regulate the activation of natural killer cells through their interaction with human leucocyte antigens (HLA). KIRs and HLA loci are highly polymorphic, and some of their combinations have been found to protect against viral infections or to predispose to autoimmune disorders. In particular, some activating KIRs profiles may be detrimental in autoimmune pathogenesis, and specific KIRs may be particularly aggressive in the clearance of different microorganisms, protecting individuals in the control of a given pathogen. So, considering that in the pathogenesis of many autoimmune disorders and infections innate immunity plays a key role, the recent …

0301 basic medicinechemical and pharmacologic phenomenaImmunogeneticsHuman leukocyte antigenCommunicable DiseasesAutoimmune DiseasesPathogenesisimmunogenetic03 medical and health sciencestranslational medicineReceptors KIRDrug DiscoveryAutoimmune diseaseotorhinolaryngologic diseasesHumansviral infections.ReceptorPathogenGenePharmacologySettore MED/04 - Patologia GeneraleInnate immune systembiologyhemic and immune systemsImmunity InnateKIR030104 developmental biologyHLA ligandImmunologybiology.proteinAntibody
researchProduct

Biomarkers and clinical characteristics of autoimmune chronic spontaneous urticaria: Results of the PURIST Study.

2019

Background: Autoimmune chronic spontaneous urticaria (aiCSU) is an important subtype of chronic spontaneous urticaria (CSU) in which functional IgG autoantibodies to IgE or its high-affinity receptor (FcεRI) induces mast cell degranulation and subsequent symptom development. However, it has not been tightly characterized. This study aimed to better define the clinical and immunological features and to explore potential biomarkers of aiCSU. Methods: This was a multinational, multicenter study of 182 CSU patients. The clinical features studied included: urticaria activity and impact (UAS7 and quality of life); autologous serum skin test (ASST); IgG anti-FcεRI and IgG anti-IgE; IgG-anti-thyrop…

0301 basic medicinechronic spontaneous urticariaMaleBasophilIgG autoantibodiesImmunoglobulin EAutoantigensHistamine Releasechemistry.chemical_compound0302 clinical medicineIron-Binding ProteinsImmunology and AllergyChronic UrticariaReceptorAutologous serum skin testbiologyDegranulationMiddle AgedChronic spontaneous urticariaAntibodies Anti-IdiotypicBasophilsmedicine.anatomical_structurePhenotypeAutologous serum skin testautologous serum skin testFemaleSymptom AssessmentHistamineAdultAdolescentImmunologyIodide PeroxidaseAutoimmune Diseases03 medical and health sciencesYoung Adultautoimmune CSUmedicineJournal ArticleHumansAgedAutoantibodiesbusiness.industryReceptors IgEAutoantibodyBasophil activation030104 developmental biology030228 respiratory systemchemistryImmunoglobulin GImmunologyBasophil activation assaysbiology.proteinAutoimmune CSUbusinessbasophil activation assaysBiomarkersAllergyREFERENCES
researchProduct

Evidence That Graves' Ophthalmopathy Immunoglobulins Do Not Directly Activate IGF-1 Receptors

2018

Background: Graves' ophthalmopathy (GO) pathogenesis involves thyrotropin (TSH) receptor (TSHR)-stimulating autoantibodies. Whether there are autoantibodies that directly stimulate insulin-like growth factor 1 receptors (IGF-1Rs), stimulating insulin-like growth factor receptor antibodies (IGFRAbs), remains controversial. This study attempted to determine whether there are stimulating IGFRAbs in patients with GO. Methods: Immunoglobulins (Igs) were purified from normal volunteers (NV-Igs) and patients with GO (GO-Igs). The effects of TSH, IGF-1, NV-Igs, and GO-Igs on pAKT and pERK1/2, members of pathways used by IGF-1R and TSHR, were compared in orbital fibroblasts from GO patients (GOFs) a…

0301 basic medicineendocrine systemendocrine system diseasesEndocrinology Diabetes and MetabolismImmunoglobulins030209 endocrinology & metabolismCell LineReceptor IGF Type 1PathogenesisGraves' ophthalmopathy03 medical and health sciences0302 clinical medicineEndocrinologymedicineHumansImmunology Autoimmunity and Graves' OphthalmopathyPhosphorylationReceptorbiologybusiness.industryAutoantibodyReceptors Thyrotropinmedicine.diseaseeye diseasesGraves Ophthalmopathy030104 developmental biologyImmunologybiology.proteinlipids (amino acids peptides and proteins)AntibodybusinessProto-Oncogene Proteins c-akthormones hormone substitutes and hormone antagonists
researchProduct

A cyclic peptide significantly improves thyroid function, thyrotropin-receptor antibodies and orbital mucine /collagen content in a long-term Graves’…

2021

BALB/c mice which received long-term immunizations of adenovirus (Ad) expressing thyrotropin receptor A-subunits (TSHR) developed stable Graves' disease (GD). TSHR-derived cyclic peptide 19 (P19) was identified as effective therapy in this model.In Ad-TSHR mice, we investigated shorter disease intervals up to 4 months for histological alterations of the orbits, fine tuning of anti-TSHR antibodies (Ab) and free thyroxine (fT4) hormone levels by using novel detection methods in an independent laboratory. Therapy (0.3 mg/kg P19 or vehicle) was given intravenously after the fourth Ad-TSHR immunization (week 11) and continued until week 19.Thyrotropin binding inhibitory immunoglobulins (TBII, br…

0301 basic medicineendocrine systemmedicine.medical_specialtyendocrine system diseasesGraves' diseaseImmunologyCellThyroid GlandPeptides CyclicThyrotropin receptorMice03 medical and health sciences0302 clinical medicineInternal medicinemedicineAnimalsHumansImmunology and AllergyBioassay030203 arthritis & rheumatologybiologymedicine.diagnostic_testbusiness.industryMucinsReceptors Thyrotropinmedicine.diseaseGraves Diseaseeye diseasesGraves OphthalmopathyDisease Models Animal030104 developmental biologymedicine.anatomical_structureEndocrinologyImmunoassaybiology.proteinFemaleCollagenAntibodyThyroid functionbusinessOrbithormones hormone substitutes and hormone antagonistsImmunoglobulins Thyroid-StimulatingHormoneJournal of Autoimmunity
researchProduct